Trial Watch – Jan Edition 2
Early-phase clinical trial intelligence from the U.S.
This edition highlights newly announced Phase 1 and Phase 2 clinical trials across oncology and neurodegenerative diseases. The focus is on trials that were initiated, approved, or reported during the second half of January 2026.
Therapeutic Areas Covered
Prostate Cancer
2 trialsANDROMEDA Trial; Phase 2
Actinium-225 vs Lutetium-177 PSMA-617 plus SBRT
What's new
On January 16, 2026, UCLA Health announced the launch of the Phase 2 ANDROMEDA trial evaluating two PSMA-targeted radioligand therapies combined with stereotactic body radiotherapy in men with recurrent oligometastatic prostate cancer.
Why it matters
This is one of the first randomized studies comparing alpha-emitting and beta-emitting PSMA therapies and may help define optimal radioligand sequencing before androgen-deprivation therapy.
ARTISAN Trial (AB001); Phase 1
Lead-212 PSMA radioligand therapy
What's new
ARTBIO reported dosing of early patient cohorts in its first-in-human Phase 1 ARTISAN study evaluating AB001 in metastatic castration-resistant prostate cancer.
Why it matters
The trial introduces lead-212–based alpha radioligand therapy and will assess safety, biodistribution and early antitumor activity in both PSMA-naïve and previously treated patients.
Alzheimer's Disease
1 trialIntermittent Deep Brain Stimulation; Phase 1
Nucleus basalis of Meynert neuromodulation
What's new
Approval was granted in January 2026 to begin a Phase 1 human clinical trial evaluating intermittent deep brain stimulation of the nucleus basalis of Meynert in early-stage Alzheimer's disease.
Why it matters
This study represents a novel non-pharmacologic approach to Alzheimer's treatment, exploring whether targeted neuromodulation can stabilize or improve cognitive function.
Colorectal Cancer
1 trial7MW4911 Antibody–Drug Conjugate; Phase I/II
Cadherin-17–targeting ADC
What's new
The first patient was dosed in a U.S. Phase I/II trial evaluating 7MW4911, a cadherin-17–targeting antibody–drug conjugate for advanced colorectal and gastrointestinal cancers.
Why it matters
This is the first human study of a CDH17-targeted ADC, a promising approach for tumors with high gastrointestinal specificity.
Breast Cancer
1 trialBBI-940 (KOMODO-1); Phase 1 Planned
Novel oral degrader targeting kinesins
What's new
In January 2026, the FDA accepted the IND application for BBI-940, enabling initiation of a first-in-human Phase 1 trial in metastatic breast cancer.
Why it matters
BBI-940 is a novel oral degrader targeting kinesins required for tumor cell division in cancers driven by extrachromosomal DNA amplification.
Key Early-Phase Trends Observed
Growing momentum in PSMA-targeted radioligand therapies
Expansion of antibody–drug conjugates into colorectal cancer
Emergence of neuromodulation approaches in Alzheimer's disease
Increased focus on precision oncology and targeted delivery platforms
Trial Watch by Kitsa
Tracking early-phase clinical trials shaping the future of drug development.
Explore Our Blogs
Keep exploring
Recommended next
- Trial Watch
Trial Watch Newsletter — January Edition 1
January 2026, Edition 1: new trial starts and design-risk callouts.
- Trial Watch
Trial Watch Newsletter — April Edition 7
April 2026, Edition 7.
- Trial Watch
Trial Watch Newsletter — February Edition 3
February 2026, Edition 3.
- Blog
Alzheimer's Trial Watch: October 2025
182 trials, 138 drugs, and the first FDA-cleared blood-based IVD for Alzheimer's diagnosis. What shaped the clinical trial pipeline in 2025.